Ann: Access Bio receives FDA clearance for COVID-19 antibody test, page-27

How interesting to (try to) figure what this approval is 'worth' on the share price - Company value. When I 'told' Atomo on the phone on Friday John said AccessBio contract revenue was worth $6mill - and $5mill to hit this Q or next, they were dumbfounded. They had no idea John said, publically, the AccessBio mimicked the NGBiotech.

Anyway, my take on this approval is AccessBio will take up their 2 mill units AND they will reup for another year as a base. So 'underlying' revenue in the danhoff calculation world is $1.5 mill a quarter - on the minimum - for the covid antibody tests. Now if this does not eventuate we will not know until Sept Q. So for now, we can live in a $1.5 mill covid base revenue per Q, but with a possibility of upside.

That leaves what SanMat correctly noted to be considered.

1. I just talked about above
2. FinFree is all over the containers on the ships, but YES YES YES this is a big key; FebriDx is approved in many jurisdictions; but Joe Hockey can likely earn his options if he lobbies in the USA to have this approval
3. This, I think, will be mini upside, but any upside is OK

The goal for me, as I have stated, is to get Q revenue up to $3 mill a Q. THEN we have a real company.